Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors

BUZZ-Street View: India's Sun Pharma Organon buy, psoriasis drug are risk factors

** Drugmaker Sun Pharma's SUN.NS Q2 profit dropped nearly 36% on one-time charge tied to Organon acquisition

** Excluding charge, profit rose 6.3%

** Shares down 1.1% at 1,759.4 rupees

ANALYSTS SEE ORGANON, ILUMYA CONCERNS

** Systematix ("Buy"; PT 2,290 rupees) says revenue and EBITDA beat driven by stronger performance across geographies on prescription growth, market-share gains and launches

** Expects innovative portfolio growth to return to double digits, with new launches adding about $1 billion in sales

** Nomura ("Buy"; PT 2,260 rupees) says sales, EBITDA and adjusted PAT beat its forecasts; sees psoriasis drug Ilumya US recovery supported by corrective steps and other approvals

** Emkay Global ("Add"; PT 2,000 rupees) cautious on Ilumya amid intensifying competition, but sees US slowdown as temporary

** ICICI Direct says Organon integration is challenging, with limited near-term growth levers and higher leverage; remains cautiously optimistic on Sun's acquisition record


(Reporting by Mridula Kumar in Bengaluru)

((Mridula.Kumar@thomsonreuters.com;))

Recent news on Sun Pharmaceutical Industries

See all news